An internal standard for the quantification of cloxacillin
Related Products
Unlabeled Version(s)
22249Cloxacillin (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cloxacillin-13C4 (sodium salt)

Item No. 28801

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(2S,5R,6R)-6-(3-(2-chlorophenyl)-5-(methyl-13C)isoxazole-4-carboxamido-13C)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, monosodium salt
Molecular Formula
C15[13C4]H17ClN3O5S • Na
Formula Weight
461.8
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: slightly solubleMethanol: slightly solubleWater: slightly soluble
SMILES
CC1(C)[C@H](C([O-])=O)N2C([C@@H](N[13C]([13C]3=[13C]([13CH3])ON=C3C4=CC=CC=C4Cl)=O)[C@@]2([H])S1)=O.[Na+]
InChi Code
InChI=1S/C19H18ClN3O5S.Na/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23;/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27);/q;+1/p-1/t13-,14+,17-;/m1./s1/i1+1,8+1,11+1,15+1;
InChi Key
SCLZRKVZRBKZCR-QSLPWVMZSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $369

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Cloxacillin-13C4 is intended for use as an internal standard for the quantification of cloxacillin (Item No. 22249) by GC- or LC-MS. Cloxacillin is a β-lactam antibiotic and a derivative of oxacillin (Item No. 23954).1 It is active against clinical isolates of the Gram-positive bacteria S. aureus and S. epidermidis (MICs = 0.004-0.4 and 0.1-0.8 µg/ml, respectively) but not 34 Gram-negative bacteria (MICs = >128 µg/ml for all).1,2 Cloxacillin binds to S. aureus penicillin-binding protein 1 (PBP1), PBP2, PBP3, and PBP4 (IC50s = 0.04, 0.12, 0.21, and 2.5 µg/ml, respectively).3 It also binds to recombinant type Ib penicillinase, as well as P. vulgaris and C. freundii cephalosporinase (Kis = 15, 0.27, and 0.027 µM, respectively).4 Cloxacillin decreases the number of staphylococci in the mammary gland in a mouse model of acute, but not chronic, mastitis induced by Staphylococcus infection.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gibbs, D.L., and Thornsberry, C. Susceptibility of gram-negative bacteria to β-lactam antibiotics and rapid characterization of β-lactamase activity. Curr. Microbiol. 2(4), 239-244 (1979).

    2. Sabath, L.D., Garner, C., Wilcox, C., et al. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob. Agents Chemother. 9(6), 962-969 (1976).

    3. Okonogi, K., Noji, Y., Nakao, M., et al. The possible physiological roles of penicillin-binding proteins of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. J. Infect. Chemother. 1(1), 50-58 (1995).

    4. Yamaguchi, A., Adachi, A., Hirata, T., et al. Conversion of cloxacillin into a progressive inhibitor of beta-lactamases by sulfonation and its activity against various types of these enzymes. J. Antibiot. (Tokyo) 38(1), 83-93 (1985).

    5. Craven, N., and Anderson, J.C. Therapy of experimental staphylococcal mastitis in the mouse with cloxacillin and rifampicin, alone and in combination. Res. Vet. Sci. 31(3), 295-300 (1981).